{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T17:10:10Z","timestamp":1795108210049,"version":"4.10.3"},"reference-count":45,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2011,1,28]],"date-time":"2011-01-28T00:00:00Z","timestamp":1296172800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arthritis &amp; Rheumatism"],"published-print":{"date-parts":[[2011,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To examine the safety and efficacy of the interleukin\u20101 (IL\u20101) receptor antagonist anakinra as first\u2010line therapy for systemic juvenile idiopathic arthritis (JIA).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients with systemic JIA receiving anakinra as part of initial disease\u2010modifying antirheumatic drug (DMARD) therapy were identified from 11 centers in 4 countries. Medical records were abstracted using a standardized instrument, and resulting data were analyzed to characterize concomitant therapies, clinical course, adverse events, and predictors of outcome.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among 46 patients meeting inclusion criteria, anakinra monotherapy was used in 10 patients (22%), while 67% received corticosteroids and 33% received additional DMARDs. Outcomes were evaluated at a median followup interval of 14.5 months. Fever and rash resolved within 1 month in &gt;95% of patients, while C\u2010reactive protein and ferritin normalized within this interval in &gt;80% of patients. Active arthritis persisted at 1 month in 39% of patients, at 3 months in 27%, and at &gt;6 months of followup in 11%. Approximately 60% of patients, including 8 of 10 receiving anakinra monotherapy, attained a complete response without escalation of therapy. Disease characteristics and treatment were similar in partial and complete responders, except that partial responders were markedly younger at onset (median age 5.2 years versus 10.2 years;\n                      <jats:italic>P<\/jats:italic>\n                      = 0.004). Associated adverse events included documented bacterial infection in 2 patients and hepatitis in 1 patient. Tachyphylaxis was not observed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Anakinra as first\u2010line therapy for systemic JIA was associated with rapid resolution of systemic symptoms and prevention of refractory arthritis in almost 90% of patients during the interval examined. These results justify further study of IL\u20101 inhibition as first\u2010line, rather than rescue, therapy in systemic JIA.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/art.30128","type":"journal-article","created":{"date-parts":[[2010,11,6]],"date-time":"2010-11-06T19:38:41Z","timestamp":1289072321000},"page":"545-555","source":"Crossref","is-referenced-by-count":417,"title":["Anakinra as first\u2010line disease\u2010modifying therapy in systemic juvenile idiopathic arthritis: Report of forty\u2010six patients from an international multicenter series"],"prefix":"10.1002","volume":"63","author":[{"given":"Peter A.","family":"Nigrovic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Mannion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Femke H. M.","family":"Prince","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Zeft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Egla","family":"Rabinovich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion A. J.","family":"van Rossum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Cortis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"Pardeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paivi M.","family":"Miettunen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ginger","family":"Janow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Birmingham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Eggebeen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Janssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew I.","family":"Shulman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Beth","family":"Son","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandy","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karla","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norman T.","family":"Ilowite","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randy Q.","family":"Cron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gloria C.","family":"Higgins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,1,28]]},"reference":[{"key":"e_1_2_7_2_2","volume-title":"Textbook of pediatric rheumatology","author":"Cassidy JT","year":"2005"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200008)43:8<1849::AID-ANR22>3.0.CO;2-F"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.090952"},{"key":"e_1_2_7_5_2","first-page":"491","article-title":"Systemic onset juvenile idiopathic arthritis: a retrospective study of 80 consecutive patients followed for 10 years","volume":"27","author":"Lomater C","year":"2000","journal-title":"J Rheumatol"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.21774"},{"key":"e_1_2_7_7_2","first-page":"394","article-title":"Health status of patients with juvenile rheumatoid arthritis at 1 and 5 years after diagnosis","volume":"30","author":"Bowyer SL","year":"2003","journal-title":"J Rheumatol"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/41.12.1428"},{"key":"e_1_2_7_9_2","first-page":"1989","article-title":"Disease course and outcome of juvenile rheumatoid arthritis in a multicenter cohort","volume":"29","author":"Oen K","year":"2002","journal-title":"J Rheumatol"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20050473"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.23437"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.076034"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0b013e3181a4f459"},{"key":"e_1_2_7_14_2","first-page":"2071","article-title":"Effective use of the recombinant interleukin 1 receptor antagonist anakinra in therapy resistant systemic onset juvenile rheumatoid arthritis","volume":"31","author":"Verbsky JW","year":"2004","journal-title":"J Rheumatol"},{"key":"e_1_2_7_15_2","first-page":"390","article-title":"International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001","volume":"31","author":"Petty RE","year":"2004","journal-title":"J Rheumatol"},{"key":"e_1_2_7_16_2","first-page":"343","article-title":"Evaluation of the presentation of systemic onset juvenile rheumatoid arthritis: data from the Pennsylvania Systemic Onset Juvenile Arthritis Registry (PASOJAR)","volume":"35","author":"Behrens EM","year":"2008","journal-title":"J Rheumatol"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keh710"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780400703"},{"key":"e_1_2_7_19_2","first-page":"2290","article-title":"Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis","volume":"31","author":"Wallace CA","year":"2004","journal-title":"J Rheumatol"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1186\/1546-0096-7-21"},{"key":"e_1_2_7_21_2","article-title":"Successful treatment of severe paediatric rheumatic disease\u2010associated macrophage activation syndrome with IL\u20101 inhibition following conventional immunosuppressive therapy: case series with 12 patients","author":"Miettunen PM","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2004-2190"},{"key":"e_1_2_7_23_2","article-title":"Combination therapy of abatacept and anakinra in children with refractory systemic juvenile idiopathic arthritis: a retrospective case series","author":"Record JL","journal-title":"J Rheumatol."},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1949.02900430001001"},{"key":"e_1_2_7_25_2","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1542\/peds.50.6.940","article-title":"Juvenile rheumatoid arthritis: a review","volume":"50","author":"Schaller J","year":"1972","journal-title":"Pediatrics"},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/0049-0172(76)90027-5"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00442095"},{"key":"e_1_2_7_28_2","first-page":"553","article-title":"Articular prognosis of the systemic form of chronic juvenile arthritis (100 cases)","volume":"30","author":"Mozziconacci P","year":"1983","journal-title":"Ann Pediatr (Paris)"},{"key":"e_1_2_7_29_2","doi-asserted-by":"publisher","DOI":"10.3109\/03009748309102900"},{"key":"e_1_2_7_30_2","doi-asserted-by":"publisher","DOI":"10.3109\/03009748709102521"},{"key":"e_1_2_7_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(05)80427-5"},{"key":"e_1_2_7_32_2","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200011)43:11<2402::AID-ANR5>3.0.CO;2-C"},{"key":"e_1_2_7_33_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.10444"},{"key":"e_1_2_7_34_2","first-page":"579","article-title":"Remission in juvenile chronic arthritis: a cohort study of 683 consecutive cases with a mean 10 year followup","volume":"30","author":"Fantini F","year":"2003","journal-title":"J Rheumatol"},{"key":"e_1_2_7_35_2","first-page":"2322","article-title":"Candidate early predictors for progression to joint damage in systemic juvenile idiopathic arthritis","volume":"33","author":"Sandborg C","year":"2006","journal-title":"J Rheumatol"},{"key":"e_1_2_7_36_2","first-page":"1151","article-title":"Global damage in systemic juvenile idiopathic arthritis: preliminary early predictors","volume":"35","author":"Russo RA","year":"2008","journal-title":"J Rheumatol"},{"key":"e_1_2_7_37_2","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.070600"},{"key":"e_1_2_7_38_2","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20044"},{"key":"e_1_2_7_39_2","first-page":"585","article-title":"Early predictors of longterm outcome in patients with juvenile rheumatoid arthritis: subset\u2010specific correlations","volume":"30","author":"Oen K","year":"2003","journal-title":"J Rheumatol"},{"key":"e_1_2_7_40_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-008-0995-9"},{"key":"e_1_2_7_41_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.25057"},{"issue":"3","key":"e_1_2_7_42_2","first-page":"iii624","article-title":"Anakinra treatment prior to steroids in newly diagnosed systemic onset JIA: changing the biology?","volume":"69","author":"Jager WD","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"e_1_2_7_43_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.20885"},{"key":"e_1_2_7_44_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.083188"},{"key":"e_1_2_7_45_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1994.03510470040032"},{"key":"e_1_2_7_46_2","doi-asserted-by":"publisher","DOI":"10.1186\/ar2619"}],"container-title":["Arthritis &amp; Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fart.30128","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/art.30128","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,23]],"date-time":"2023-11-23T08:35:05Z","timestamp":1700728505000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/art.30128"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1,28]]},"references-count":45,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,2]]}},"alternative-id":["10.1002\/art.30128"],"URL":"https:\/\/doi.org\/10.1002\/art.30128","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.718303449.793491944","asserted-by":"object"}]},"ISSN":["0004-3591","1529-0131"],"issn-type":[{"value":"0004-3591","type":"print"},{"value":"1529-0131","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,1,28]]}}}